Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies

Pharmaceuticals

Volumn 3, Issue 8, 2010, Pages 2441-2469

  Ellis, Leigh ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Apoptosis; Autophagy; Cancer; Clinical trial; Epigenetic therapy; Epigenetics; HDAC; HDAC inhibitors; Pre clinical

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; BORTEZOMIB; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOCETAXEL; DOXORUBICIN; ENTINOSTAT; EPIRUBICIN; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXALIPLATIN; PANOBINOSTAT; ROMIDEPSIN; SORAFENIB; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; ASTROCYTOMA; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG STRUCTURE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION PROFILING; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROBLASTOMA; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PLEIOTROPY; PROSTATE CANCER; PROTEIN INTERACTION; REVIEW; SEPSIS; STOMACH CANCER; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 77955581767     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3082441     Document Type: Review

References (148)

1. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128, 683-692.
2. Ellis, L.; Atadja, P.W.; Johnstone, R.W. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther. 2009, 8, 1409-1420.
3. Marks, P.A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25, 84-90.
4. Campas-Moya, C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 2009, 45, 787-795.
5. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5, 769-784.
6. Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009, 280, 145-153.
7. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M.L.; Rehman, M.; Walther, T.C.; Olsen, J.V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325, 834-840.
8. Glozak, M.A.; Seto, E. Histone deacetylases and cancer. Oncogene. 2007, 26, 5420-5432.
9. de Ruijter, A.J.; van Gennip, A.H.; Caron, H.N.; Kemp, S.; van Kuilenburg, A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-749.
10. Haigis, M.C.; Guarente, L.P. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20, 2913-2921.
11. Nakagawa, M.; Oda, Y.; Eguchi, T.; Aishima, S.; Yao, T.; Hosoi, F.; Basaki, Y.; Ono, M.; Kuwano, M.; Tanaka, M.; Tsuneyoshi, M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18, 769-774.
12. Weichert, W.; Roske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; Fritzsche, F.R.; Niesporek, S.; Denkert, C.; Dietel, M.; Kristiansen, G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer. 2008, 98, 604-610.
13. Halkidou, K.; Gaughan, L.; Cook, S.; Leung, H.Y.; Neal, D.E.; Robson, C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59, 177-189.
14. Halkidou, K.; Cook, S.; Leung, H.Y.; Neal, D.E.; Robson, C.N. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur. Urol. 2004, 45, 382-389; author reply 389.
15. Park, J.M.; Lee, G.Y.; Choi, J.E.; Kang, H.G.; Jang, J.S.; Cha, S.I.; Lee, E.B.; Kim, S.G.; Kim, C.H.; Lee, W.K.; Kam, S.; Kim, D.S.; Jung, T.H.; Park, J.Y. No association between polymorphisms in the histone deacetylase genes and the risk of lung cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 1841-1843.
16. Cebrian, A.; Pharoah, P.D.; Ahmed, S.; Ropero, S.; Fraga, M.F.; Smith, P.L.; Conroy, D.; Luben, R.; Perkins, B.; Easton, D.F.; Dunning, A.M.; Esteller, M.; Ponder, B.A. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 2006, 27, 1661-1669.
17. Ozdag, H.; Teschendorff, A.E.; Ahmed, A.A.; Hyland, S.J.; Blenkiron, C.; Bobrow, L.; Veerakumarasivam, A.; Burtt, G.; Subkhankulova, T.; Arends, M.J.; Collins, V.P.; Bowtell, D.; Kouzarides, T.; Brenton, J.D.; Caldas, C. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006, 7, 90.
18. Ropero, S.; Fraga, M.F.; Ballestar, E.; Hamelin, R.; Yamamoto, H.; Boix-Chornet, M.; Caballero, R.; Alaminos, M.; Setien, F.; Paz, M.F.; Herranz, M.; Palacios, J.; Arango, D.; Orntoft, T.F.; Aaltonen, L.A.; Schwartz, S., Jr.; Esteller, M. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006, 38, 566-569.
19. Sjoblom, T.; Jones, S.; Wood, L.D.; Parsons, D.W.; Lin, J.; Barber, T.D.; Mandelker, D.; Leary, R.J.; Ptak, J.; Silliman, N.; Szabo, S.; Buckhaults, P.; Farrell, C.; Meeh, P.; Markowitz, S.D.; Willis, J.; Dawson, D.; Willson, J.K.; Gazdar, A.F.; Hartigan, J.; Wu, L.; Liu, C.; Parmigiani, G.; Park, B.H.; Bachman, K.E.; Papadopoulos, N.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274.
20. Marquard, L.; Gjerdrum, L.M.; Christensen, I.J.; Jensen, P.B.; Sehested, M.; Ralfkiaer, E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008, 53, 267-277.
21. Zelent, A.; Guidez, F.; Melnick, A.; Waxman, S.; Licht, J.D. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 2001, 20, 7186-7203.
22. Pandolfi, P.P. Transcription therapy for cancer. Oncogene 2001, 20, 3116-3127.
23. Lin, R.J.; Sternsdorf, T.; Tini, M.; Evans, R.M. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001, 20, 7204-7215.
24. Cress, W.D.; Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 2000, 184, 1-16.
25. Bhalla, K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 2005, 23, 3971-3993.
26. Bereshchenko, O.R.; Gu, W.; Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 2002, 32, 606-613.
27. Weichert, W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009, 280, 168-176.
28. Witt, O.; Deubzer, H.E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009, 277, 8-21.
29. Schrump, D.S. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res. 2009, 15, 3947-3957.
30. Miremadi, A.; Oestergaard, M.Z.; Pharoah, P.D.; Caldas, C. Cancer genetics of epigenetic genes. Hum. Mol. Genet. 2007, 16 (Special No. 1), R28-R49.
31. Peart, M.J.; Smyth, G.K.; van Laar, R.K.; Bowtell, D.D.; Richon, V.M.; Marks, P.A.; Holloway, A.J.; Johnstone, R.W. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102, 3697-3702.
32. Mitsiades, C.S.; Mitsiades, N.S.; McMullan, C.J.; Poulaki, V.; Shringarpure, R.; Hideshima, T.; Akiyama, M.; Chauhan, D.; Munshi, N.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T.A.; Richon, V.M.; Marks, P.A.; Anderson, K.C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA 2004, 101, 540-545.
33. Moore, P.S.; Barbi, S.; Donadelli, M.; Costanzo, C.; Bassi, C.; Palmieri, M.; Scarpa, A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A revealsaltered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta 2004, 1693, 167-176.
34. Glaser, K.B.; Staver, M.J.; Waring, J.F.; Stender, J.; Ulrich, R.G.; Davidsen, S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003, 2, 151-163.
35. Gray, S.G.; Qian, C.N.; Furge, K.; Guo, X.; Teh, B.T. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int. J. Oncol. 2004, 24, 773-795.
36. Crabb, S.J.; Howell, M.; Rogers, H.; Ishfaq, M.; Yurek-George, A.; Carey, K.; Pickering, B.M.; East, P.; Mitter, R.; Maeda, S.; Johnson, P.W.; Townsend, P.; Shin-ya, K.; Yoshida, M.; Ganesan, A.; Packham, G. Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem. Pharmacol. 2008, 76, 463-475.
37. Schrump, D.S.; Fischette, M.R.; Nguyen, D.M.; Zhao, M.; Li, X.; Kunst, T.F.; Hancox, A.; Hong, J.A.; Chen, G.A.; Kruchin, E.; Wright, J.J.; Rosing, D.R.; Sparreboom, A.; Figg, W.D.; Steinberg, S.M. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin. Cancer Res. 2008, 14, 188-198.
38. Ellis, L.; Pan, Y.; Smyth, G.K.; George, D.J.; McCormack, C.; Williams-Truax, R.; Mita, M.; Beck, J.; Burris, H.; Ryan, G.; Atadja, P.; Butterfoss, D.; Dugan, M.; Culver, K.; Johnstone, R.W.; Prince, H.M. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res. 2008, 14, 4500-4510.
39. Johnstone, R.W.; Licht, J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003, 4, 13-18.
40. Glozak, M.A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363, 15-23.
41. Spange, S.; Wagner, T.; Heinzel, T.; Kramer, O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009, 41, 185-198.
42. Vousden, K.H.; Lane, D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8, 275-283.
43. Vervoorts, J.; Luscher-Firzlaff, J.; Luscher, B. The ins and outs of MYC regulation by posttranslational mechanisms. J. Biol. Chem. 2006, 281, 34725-34729.
44. Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A.K.; Simms-Waldrip, T.; Fu, C.; Sakamoto, K.M. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res. 2008, 68, 2557-2560.
45. Simms-Waldrip, T.; Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A.K.; Fu, C.; Sakamoto, K.M. The aggresome pathway as a target for therapy in hematologic malignancies. Mol. Genet. Metab. 2008, 94, 283-286.
46. Adams, R.H.; Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 2007, 8, 464-478.
47. Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358, 2039-2049.
48. Lin, E.Y.; Pollard, J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007, 67, 5064-5066.
49. Kim, M.S.; Kwon, H.J.; Lee, Y.M.; Baek, J.H.; Jang, J.E.; Lee, S.W.; Moon, E.J.; Kim, H.S.; Lee, S.K.; Chung, H.Y.; Kim, C.W.; Kim, K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001, 7, 437-443.
50. Mahon, P.C.; Hirota, K.; Semenza, G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15, 2675-2686.
51. Fath, D.M.; Kong, X.; Liang, D.; Lin, Z.; Chou, A.; Jiang, Y.; Fang, J.; Caro, J.; Sang, N. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J. Biol. Chem. 2006, 281, 13612-13619.
52. Qian, D.Z.; Kachhap, S.K.; Collis, S.J.; Verheul, H.M.; Carducci, M.A.; Atadja, P.; Pili, R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006, 66, 8814-8821.
53. Kong, X.; Lin, Z.; Liang, D.; Fath, D.; Sang, N.; Caro, J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell Biol. 2006, 26, 2019-2028.
54. Kim, S.H.; Jeong, J.W.; Park, J.A.; Lee, J.W.; Seo, J.H.; Jung, B.K.; Bae, M.K.; Kim, K.W. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol. Rep. 2007, 17, 647-651.
55. Kato, H.; Tamamizu-Kato, S.; Shibasaki, F. Histone deacetylase 7 associates with hypoxiainducible factor 1alpha and increases transcriptional activity. J. Biol. Chem. 2004, 279, 41966-41974.
56. Mottet, D.; Bellahcene, A.; Pirotte, S.; Waltregny, D.; Deroanne, C.; Lamour, V.; Lidereau, R.; Castronovo, V. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ. Res. 2007, 101, 1237-1246.
57. Liu, T.; Kuljaca, S.; Tee, A.; Marshall, G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev. 2006, 32, 157-165.
58. Kwon, H.J.; Kim, M.S.; Kim, M.J.; Nakajima, H.; Kim, K.W. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 2002, 97, 290-296.
59. Qian, D.Z.; Wang, X.; Kachhap, S.K.; Kato, Y.; Wei, Y.; Zhang, L.; Atadja, P.; Pili, R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004, 64, 6626-6634.
60. Sasakawa, Y.; Naoe, Y.; Noto, T.; Inoue, T.; Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, S. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. 2003, 66, 897-906.
61. Zgouras, D.; Becker, U.; Loitsch, S.; Stein, J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem. Biophys. Res. Commun. 2004, 316, 693-697.
62. Kang, J.H.; Kim, M.J.; Chang, S.Y.; Sim, S.S.; Kim, M.S.; Jo, Y.H. CCAAT box is required for the induction of human thrombospondin-1 gene by trichostatin A. J. Cell. Biochem. 2008, 104, 1192-1203.
63. LaBonte, M.J.; Wilson, P.M.; Fazzone, W.; Groshen, S.; Lenz, H.J.; Ladner, R.D. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med. Genomics 2009, 2, 67.
64. Mie Lee, Y.; Kim, S.H.; Kim, H.S.; Jin Son, M.; Nakajima, H.; Jeong Kwon, H.; Kim, K.W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 2003, 300, 241-246.
65. Deroanne, C.F.; Bonjean, K.; Servotte, S.; Devy, L.; Colige, A.; Clausse, N.; Blacher, S.; Verdin, E.; Foidart, J.M.; Nusgens, B.V.; Castronovo, V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002, 21, 427-436.
66. Rossig, L.; Li, H.; Fisslthaler, B.; Urbich, C.; Fleming, I.; Forstermann, U.; Zeiher, A.M.; Dimmeler, S. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 2002, 91, 837-844.
67. Michaelis, M.; Suhan, T.; Cinatl, J.; Driever, P.H.; Cinatl, J., Jr. Valproic acid and interferonalpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int. J. Oncol. 2004, 25, 1795-1799.
68. Michaelis, M.; Michaelis, U.R.; Fleming, I.; Suhan, T.; Cinatl, J.; Blaheta, R.A.; Hoffmann, K.; Kotchetkov, R.; Busse, R.; Nau, H.; Cinatl, J., Jr. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol. Pharmacol. 2004, 65, 520-527.
69. Hellebrekers, D.M.; Melotte, V.; Vire, E.; Langenkamp, E.; Molema, G.; Fuks, F.; Herman, J.G.; Van Criekinge, W.; Griffioen, A.W.; van Engeland, M. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 2007, 67, 4138-4148.
70. Yu, C.; Friday, B.B.; Lai, J.P.; McCollum, A.; Atadja, P.; Roberts, L.R.; Adjei, A.A. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitorinduced apoptosis through reactive oxygen species generation. Clin. Cancer Res. 2007, 13, 1140-1148.
71. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M.M.; Simons, J.W.; Semenza, G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60, 1541-1545.
72. Verheul, H.M.; Salumbides, B.; Van Erp, K.; Hammers, H.; Qian, D.Z.; Sanni, T.; Atadja, P.; Pili, R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin. Cancer Res. 2008, 14, 3589-3597.
73. Murakami, J.; Asaumi, J.; Maki, Y.; Tsujigiwa, H.; Kuroda, M.; Nagai, N.; Yanagi, Y.; Inoue, T.; Kawasaki, S.; Tanaka, N.; Matsubara, N.; Kishi, K. Effects of demethylating agent 5-aza-2(')- deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines. Oral Oncol. 2004, 40, 597-603.
74. Hellebrekers, D.M.; Castermans, K.; Vire, E.; Dings, R.P.; Hoebers, N.T.; Mayo, K.H.; Oude Egbrink, M.G.; Molema, G.; Fuks, F.; van Engeland, M.; Griffioen, A.W. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006, 66, 10770-10777.
75. Suuronen, T.; Nuutinen, T.; Ryhanen, T.; Kaarniranta, K.; Salminen, A. Epigenetic regulation of clusterin/apolipoprotein J expression in retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 2007, 357, 397-401.
76. Carew, J.S.; Medina, E.C.; Esquivel, J.A., Mahalingam, D.; Swords, R.; Kelly, K.; Zhang, H.; Huang, P.; Mita, A.C.; Mita, M.M.; Giles, F.J.; Nawrocki, S.T. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J. Cell. Mol. Med. 2009, doi:10.1111/j.1582-4934.2009.00832.x.
77. Crighton, D.; Wilkinson, S.; O'Prey, J.; Syed, N.; Smith, P.; Harrison, P.R.; Gasco, M.; Garrone, O.; Crook, T.; Ryan, K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126, 121-134.
78. Crighton, D.; O'Prey, J.; Bell, H.S.; Ryan, K.M. p73 regulates DRAM-independent autophagy that does not contribute to programmed cell death. Cell Death Differ. 2007, 14, 1071-1079.
79. Rosenbluth, J.M.; Mays, D.J.; Pino, M.F.; Tang, L.J.; Pietenpol, J.A. A gene signature-based approach identifies mTOR as a regulator of p73. Mol. Cell Biol. 2008, 28, 5951-5964.
80. Rosenbluth, J.M.; Pietenpol, J.A. mTOR regulates autophagy-associated genes downstream of p73. Autophagy 2009, 5, 114-116.
81. Oh, M.; Choi, I.K.; Kwon, H.J. Inhibition of histone deacetylase1 induces autophagy. Biochem. Biophys. Res. Commun. 2008, 369, 1179-1183.
82. Iwata, A.; Riley, B.E.; Johnston, J.A.; Kopito, R.R. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 2005, 280, 40282-40292.
83. Shao, Y.; Gao, Z.; Marks, P.A.; Jiang, X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2004, 101, 18030-18035.
84. Carew, J.S.; Nawrocki, S.T.; Kahue, C.N.; Zhang, H.; Yang, C.; Chung, L.; Houghton, J.A.; Huang, P.; Giles, F.J.; Cleveland, J.L. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007, 110, 313-322.
85. Walker, T.; Mitchell, C.; Park, M.A.; Yacoub, A.; Graf, M.; Rahmani, M.; Houghton, P.J.; Voelkel-Johnson, C.; Grant, S.; Dent, P. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol. Pharmacol. 2009, 76, 342-355.
86. Cao, Q.; Yu, C.; Xue, R.; Hsueh, W.; Pan, P.; Chen, Z.; Wang, S.; McNutt, M.; Gu, J. Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. Int. J. Biochem. Cell Biol. 2008, 40, 272-283.
87. Hrzenjak, A.; Kremser, M.L.; Strohmeier, B.; Moinfar, F.; Zatloukal, K.; Denk, H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J. Pathol. 2008, 216, 495-504.
88. Ellis, L.; Bots, M.; Lindemann, R.K.; Bolden, J.E.; Newbold, A.; Cluse, L.A.; Scott, C.L.; Strasser, A.; Atadja, P.; Lowe, S.W.; Johnstone, R.W. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009, 114, 380-393.
89. Meech, S.J.; Edelson, R.; Walsh, P.; Norris, D.A.; Duke, R.C. Reversible resistance to apoptosis in cutaneous T cell lymphoma. Ann. N. Y. Acad. Sci. 2001, 941, 46-58.
90. Cory, S.; Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
91. Vermeulen, K.; Van Bockstaele, D.R.; Berneman, Z.N. Apoptosis: mechanisms and relevance in cancer. Ann. Hematol. 2005, 84, 627-639.
92. Rossi, D.; Gaidano, G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003, 88, 212-218.
93. Thornberry, N.A.; Lazebnik, Y. Caspases: enemies within. Science. 1998, 281, 1312-1316.
94. Johnstone, R.W.; Ruefli, A.A.; Lowe, S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108, 153-164.
95. Rosato, R.R.; Grant, S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin. Ther. Targets 2005, 9, 809-824.
96. Minucci, S.; Pelicci, P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38-51.
97. Dokmanovic, M.; Marks, P.A. Prospects: histone deacetylase inhibitors. J. Cell Biochem. 2005, 96, 293-304.
98. Lindemann, R.K.; Gabrielli, B.; Johnstone, R.W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004, 3, 779-788.
99. Fantin, V.R.; Loboda, A.; Paweletz, C.P.; Hendrickson, R.C.; Pierce, J.W.; Roth, J.A.; Li, L.; Gooden, F.; Korenchuk, S.; Hou, X.S.; Harrington, E.A.; Randolph, S.; Reilly, J.F.; Ware, C.M.; Kadin, M.E.; Frankel, S.R.; Richon, V.M. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008, 68, 3785-3794.
100. Johnstone, R.W.; Frew, A.J.; Smyth, M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer. 2008, 8, 782-798.
101. Frew, A.J.; Lindemann, R.K.; Martin, B.P.; Clarke, C.J.; Sharkey, J.; Anthony, D.A.; Banks, K.M.; Haynes, N.M.; Gangatirkar, P.; Stanley, K.; Bolden, J.E.; Takeda, K.; Yagita, H.; Secrist, J.P.; Smyth, M.J.; Johnstone, R.W. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl. Acad. Sci. USA 2008, 105, 11317-11322.
102. Earel, J.K., Jr.; VanOosten, R.L.; Griffith, T.S. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006, 66, 499-507.
103. Kauh, J.; Fan, S.; Xia, M.; Yue, P.; Yang, L.; Khuri, F.R.; Sun, S.Y. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 2010, 5, e10376.
104. Xu, W.; Ngo, L.; Perez, G.; Dokmanovic, M.; Marks, P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl. Acad. Sci. USA 2006, 103, 15540-15545.
105. Nebbioso, A.; Clarke, N.; Voltz, E.; Germain, E.; Ambrosino, C.; Bontempo, P.; Alvarez, R.; Schiavone, E.M.; Ferrara, F.; Bresciani, F.; Weisz, A.; de Lera, A.R.; Gronemeyer, H.; Altucci, L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11, 77-84.
106. Insinga, A.; Monestiroli, S.; Ronzoni, S.; Gelmetti, V.; Marchesi, F.; Viale, A.; Altucci, L.; Nervi, C.; Minucci, S.; Pelicci, P.G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 2005, 11, 71-76.
107. Nakata, S.; Yoshida, T.; Horinaka, M.; Shiraishi, T.; Wakada, M.; Sakai, T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004, 23, 6261-6271.
108. Singh, T.R.; Shankar, S.; Srivastava, R.K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005, 24, 4609-4623.
109. MacFarlane, M.; Inoue, S.; Kohlhaas, S.L.; Majid, A.; Harper, N.; Kennedy, D.B.; Dyer, M.J.; Cohen, G.M. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 2005, 12, 773-782.
110. Imai, T.; Adachi, S.; Nishijo, K.; Ohgushi, M.; Okada, M.; Yasumi, T.; Watanabe, K.; Nishikomori, R.; Nakayama, T.; Yonehara, S.; Toguchida, J.; Nakahata, T. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 2003, 22, 9231-9242.
111. Sutheesophon, K.; Nishimura, N.; Kobayashi, Y.; Furukawa, Y.; Kawano, M.; Itoh, K.; Kano, Y.; Ishii, H.; Furukawa, Y. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J. Cell Physiol. 2005, 203, 387-397.
112. de Ruijter, A.J.; Meinsma, R.J.; Bosma, P.; Kemp, S.; Caron, H.N.; van Kuilenburg, A.B. Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. Exp. Cell Res. 2005, 309, 451-467.
113. Zhang, X.D.; Gillespie, S.K.; Borrow, J.M.; Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 2004, 3, 425-435.
114. Sanda, T.; Okamoto, T.; Uchida, Y.; Nakagawa, H.; Iida, S.; Kayukawa, S.; Suzuki, T.; Oshizawa, T.; Miyata, N.; Ueda, R. Proteome analyses of the growth inhibitory effects of NCH- 51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 2007, 21, 2344-2353.
115. Rosato, R.R.; Maggio, S.C.; Almenara, J.A.; Payne, S.G.; Atadja, P.; Spiegel, S.; Dent, P.; Grant, S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinasedependent generation of ceramide. Mol. Pharmacol. 2006, 69, 216-225.
116. Ruefli, A.A.; Ausserlechner, M.J.; Bernhard, D.; Sutton, V.R.; Tainton, K.M.; Kofler, R.; Smyth, M.J.; Johnstone, R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 2001, 98, 10833-10838.
117. Peart, M.J.; Tainton, K.M.; Ruefli, A.A.; Dear, A.E.; Sedelies, K.A.; O'Reilly, L.A.; Waterhouse, N.J.; Trapani, J.A.; Johnstone, R.W. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003, 63, 4460-4471.
118. Lindemann, R.K.; Newbold, A.; Whitecross, K.F.; Cluse, L.A.; Frew, A.J.; Ellis, L.; Williams, S.; Wiegmans, A.P.; Dear, A.E.; Scott, C.L.; Pellegrini, M.; Wei, A.; Richon, V.M.; Marks, P.A.; Lowe, S.W.; Smyth, M.J.; Johnstone, R.W. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl. Acad. Sci. USA 2007, 104, 8071-8076.
119. Zhao, Y.; Tan, J.; Zhuang, L.; Jiang, X.; Liu, E.T.; Yu, Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl. Acad. Sci. USA 2005, 102, 16090-16095.
120. Inoue, S.; Riley, J.; Gant, T.W.; Dyer, M.J.; Cohen, G.M. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007, 21, 1773-1782.
121. Zhang, Y.; Adachi, M.; Kawamura, R.; Imai, K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ. 2006, 13, 129-140.
122. Li, P.; Wang, D.; Yao, H.; Doret, P.; Hao, G.; Shen, Q.; Qiu, H.; Zhang, X.; Wang, Y.; Chen, G. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 29, 3153-3162.
123. Mahalingam, D.; Medina, E.C.; Esquivel, J.A., Espitia, C.M.; Smith, S.; Oberheu, K.; Swords, R.; Kelly, K.R.; Mita, M.M.; Mita, A.C.; Carew, J.S.; Giles, F.J.; Nawrocki, S.T. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16, 141-153.
124. Yip, K.W.; Reed, J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27, 6398-6406.
125. Whitecross, K.F.; Alsop, A.E.; Cluse, L.A.; Wiegmans, A.; Banks, K.M.; Coomans, C.; Peart, M.J.; Newbold, A.; Lindemann, R.K.; Johnstone, R.W. Defining the target specificity of ABT- 737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009, 113, 1982-1991.
126. Park, C.M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K.C.; Nimmer, P.; Shoemaker, A.R.; Song, X.; Tahir, S.K.; Tse, C.; Wang, X.; Wendt, M.D.; Yang, X.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H.; Elmore, S.W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 2008, 51, 6902-6915.
127. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; Roberts, L.; Tahir, S.K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S.H.; Elmore, S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68, 3421-3428.
128. Tan, J.; Cang, S.; Ma, Y.; Petrillo, R.L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 3, 5.
129. Siegel, D.; Hussein, M.; Belani, C.; Robert, F.; Galanis, E.; Richon, V.M.; Garcia-Vargas, J.; Sanz-Rodriguez, C.; Rizvi, S. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2009, 2, 31.
130. Ramalingam, S.S.; Parise, R.A.; Ramanathan, R.K.; Lagattuta, T.F.; Musguire, L.A.; Stoller, R.G.; Potter, D.M.; Argiris, A.E.; Zwiebel, J.A.; Egorin, M.J.; Belani, C.P. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 2007, 13, 3605-3610.
131. Fakih, M.G.; Pendyala, L.; Fetterly, G.; Toth, K.; Zwiebel, J.A.; Espinoza-Delgado, I.; Litwin, A.; Rustum, Y.M.; Ross, M.E.; Holleran, J.L.; Egorin, M.J. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin. Cancer Res. 2009, 15, 3189-3195.
132. Munster, P.N.; Marchion, D.; Thomas, S.; Egorin, M.; Minton, S.; Springett, G.; Lee, J.H.; Simon, G.; Chiappori, A.; Sullivan, D.; Daud, A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 2009, 101, 1044-1050.
133. Schneider, B.J.; Bradley, D.; Smith, D.C.; Egorin, M.; Kalemkerian, G.; Dunn, R.; Daignault, S.; Hussain, M. Phase I study of vorinostat plus docetaxel in patients with solid tumor maligancies. J. Clin. Oncol. 2009, 27, Abstr. 2528.
134. Tredaniel, J.; Descourt, R.; Moro-Sibilot, D.; Misset, J.; Gachard, E.; Garcia-Vargas, J.; Roben, E.; Zalcman, G. Vorinostat in combination with gemcitibine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A phase I dose-escalation study. J. Clin. Oncol. 2009, 27, Abstr. 8049.
135. Reguart, N.; Cardona, A.F.; Isla, D.; Cardenal, F.; Palmero, R.; Carrasco-Chaumel, E.; Rolfo, C.; Massuti, B. Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression. J. Clin. Oncol. 2009, 27, Abstr. e19057.
136. Ninan, J.A.; Bailey, H.; Kolesar, J. Marnocha, R.; Eickoff, J.; Wright, J.; Espinoza-Delgado, I.; Aberti, D.; Wilding, G.; Schelman, W. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J. Clin. Oncol. 2009, 27, Abstr. 2531.
137. Doss, H.H.; Jones, S.F.; Infante, J.R.; Spigel, D.R.; Willcutt, N.; Lamar, R.; Barton, J.; Keegan, M.; Burris, H.A. A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J. Clin. Oncol. 2008, 26, Abstr. 2567
138. Berenson, J.R.; Yellin, O.; Mapes, R.; Eades, B.; Abaya, C.D.; Strayer, A.; Nix, D.; Swift, R.A. A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. J. Clin. Oncol. 2009, 27, Abstr. e19508.
139. Konduri, K.; Spira, A.I.; Jotte, R.M.; Boyd, T.; Gaffar Y.A., Reynolds, C.; Witta, S.E. Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC. J. Clin. Oncol. 2009, 27, Abstr. e14545.
140. Juergens, R.A.; Vendetti, F.; Coleman, B.; Sebree, R.S.; Rudek, M.A.; Belinsky, S.; Brock, M.; Herman, J.; Baylin, S.; Rudin, C.M. Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). J. Clin. Oncol. 2009, 27, Abstr. 8055.
141. Conte, P.; Campone, M.; Pronzato, P.; Amadori, D.; Frank, R.; Shuetz, F.; Rea, D.; Wardley, A.; Britten, C.; Elias, A. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. J. Clin. Oncol. 2009, 27, Abstr. 1081.
142. Spencer, A.; Taylor, K.; Lonial, S.; Mateos, M.V.; Jalaluddin, M.; Hazell, K.; Bourquelot, P.M.; San Miguel, J.F. Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). J. Clin. Oncol. 2009, 27, Abstr. 8542.
143. Rathkopf, D.E.; Chi, K.N.; Vaishampayan, U.; Hotte, S.; Vogelzang, N.; Alumkal, J.; Agrawal, M.; Hydam, T.M.; Fandi, A.; Scher, H.I. Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). J. Clin. Oncol. 2009, 27, Abstr. 5064.
144. Pili, R.; Lodge, M.; Verheul, H.; Mashtare, T.; Wahl, R.L.; Martin, J.E.; Espinoza-Delgado, I.; Liu, G.; Carducci, M.A. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in pre-treated patients with renal cell carcinoma: safety, efficacy and pharmacodynamic results. In ASCO 2010 Genitourinary Cancers Symposium, San Francisco, CA, USA, 5-7 March 2010; Abstr. 350.
145. Dasari, A.; Gore, L.; Messersmith, W.A.; Diab, S.; Jimeno, A.; Weekes, C.D.; Lewis, K.D.; Drabkin, H.A.; Flaig, T.W.; Camidge, D.R. A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II (renal and non-small cell lung carcinoma). J. Clin. Oncol. 2010, 28, Abstr. 2562.
146. Dickson, M.A.; Rathkopf, D.E.; Grant, S.; Roberts, J.D.; Reid, J.M.; Ames, M.M.; McGovern, R.M.; Gonen, M.; Dials, H.J.; Schwartz, G.K. Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors. J. Clin. Oncol. 2010, 28, Abstr. e13511.
147. Munster, P.N.; Petrou, P.; Ryan, C.J.; Jahan, T.M.; DuBois, S.G.; Rugo, H.S.; Chan, J.K.; Thurn, K.T.; Reinert, A.; Daud, A. A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with with solid tumor malignancies. J. Clin. Oncol. 2010, 28, Abstr. e13140.
148. Wardley, A.M.; Stein, R.; McCaffrey, J.; Crown, J.; Malik, Z.; Rea, D.; Barrett-Lee, P.J.; Lee, G.T. Phase II data for entinostat, a class I selective inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy. J. Clin. Oncol. 2010, 28, Abstr. 1052.